Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Drug Development Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Investor Overview

Stock quote
  
 
VOLUME:
View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases
March 15, 2021
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
February 25, 2021
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
February 22, 2021
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
View all »
Events
Mar 16, 2021
10:00 AM EDT
Aclaris Therapeutics, Inc. at Oppenheimer 31st Annual Healthcare Conference
Mar 9, 2021
7:00 AM EST
Aclaris Therapeutics, Inc. at H.C. Wainwright Global Life Sciences Conference
Feb 25, 2021
8:00 AM EST
Aclaris Therapeutics, Inc. at 10th Annual SVB Leerink Global Healthcare Conference
View all »
Feature Presentation
Aclaris Therapeutics Company Overview - March 2021

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.